All In Biotech

Drug Trial Radar · NCT07010159

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

A Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent Pericarditis

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

325

Planned (sponsor's estimate)

Start

Jul 25, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2029

Sponsor

Sponsor type
Industry
Collaborators
Kiniksa Pharmaceuticals, GmbH
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.

Conditions

  • Pericarditis
  • Pericarditis Acute
  • Recurrent Pericarditis

Interventions

  • KPL-387Drug

    administered by subcutaneous injection

  • PlaceboDrug

    administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Time to Treatment Response by Week 24Time frame: From Baseline up to Week 24
  2. Phase 3: Time to Pericarditis RecurrenceTime frame: From Baseline in the RW Period
  3. Long-Term Extension: Annualized rate of Pericarditis RecurrenceTime frame: Up to 24 Months

Locations

67 sites in 10 countries. Site status is shown where the registry gives one.

  • Investigational Site 018

    Gilbert, Arizona · Recruiting

  • Investigational Site 053

    Phoenix, Arizona · Recruiting

  • Investigational Site 064

    La Jolla, California · Recruiting

  • Investigational Site 030

    Los Angeles, California · Recruiting

  • Investigational Site 008

    San Francisco, California · Recruiting

  • Investigational Site 044

    Santa Monica, California · Recruiting

  • Investigational Site 058

    Ventura, California · Recruiting

  • Investigational Site 016

    Westminster, Colorado · Recruiting

  • Investigational Site 061

    Washington D.C., District of Columbia · Recruiting

  • Investigational Site 067

    Kissimmee, Florida · Recruiting

  • Investigational Site 001

    Columbus, Georgia · Withdrawn

  • Investigational Site 004

    Chicago, Illinois · Recruiting

  • Investigational Site 014

    Indianapolis, Indiana · Recruiting

  • Investigational Site 002

    Overland Park, Kansas · Withdrawn

  • Investigational Site 043

    Baltimore, Maryland · Recruiting

  • Investigational Site 054

    Boston, Massachusetts · Recruiting

  • Investigational Site 055

    Minneapolis, Minnesota · Recruiting

  • Investigational Site 012

    Rochester, Minnesota · Recruiting

  • Investigational Site 050

    Kansas City, Missouri · Recruiting

  • Investigational Site 046

    Kansas City, Missouri · Recruiting

  • Investigational Site 062

    St Louis, Missouri · Recruiting

  • Investigational Site 015

    New York, New York · Recruiting

  • Investigational Site 022

    New York, New York · Recruiting

  • Investigational Site 009

    Cincinnati, Ohio · Recruiting

  • Investigational Site 003

    Cleveland, Ohio · Recruiting

  • Investigational Site 005

    Austin, Texas · Recruiting

  • Investigational Site 066

    Houston, Texas · Recruiting

  • Investigational Site 013

    Houston, Texas · Recruiting

  • Investigational Site 042

    Burlington, Vermont · Recruiting

  • Investigational Site 006

    Charlottesville, Virginia · Recruiting

  • Investigational Site 023

    Norfolk, Virginia · Recruiting

  • Investigational Site 045

    Richmond, Virginia · Recruiting

  • Investigational Site 065

    Seattle, Washington · Recruiting

  • Investigational Site 027

    Ottawa, Ontario, Canada · Recruiting

  • Investigational Site 028

    Montpellier, France · Recruiting

  • Investigational Site 021

    Paris, France · Recruiting

  • Investigational Site 036

    Pessac, France · Recruiting

  • Investigational Site 019

    Poitiers, France · Recruiting

  • Investigational Site 037

    Toulouse, France · Recruiting

  • Investigational Site 038

    Toulouse, France · Recruiting

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.